PEGASUS, NCT02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer |
|
|
| Active, not recruiting | 3 | 885 | Europe | Degarelix, approved GnRH agonist, Radiotherapy | European Organisation for Research and Treatment of Cancer - EORTC | Prostate Cancer | 08/23 | 06/26 | | |
| Recruiting | N/A | 35 | Europe | Radiotherapy with MRIdian with simultaneous integrated boost, Radiotherapy with MRIdian (ViewRay Inc.), Questionnaires before, during and after radiotherapy | Universitair Ziekenhuis Brussel | Rectal Cancer | 06/25 | 06/30 | | |
THUNDER, NCT06282588: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers |
|
|
| Recruiting | 2/3 | 493 | Europe | Darolutamide, Nubeqa, BAY1841788, Darolutamide matched placebo, BAY1841788 matched placebo, Radiotherapy, Zoladex 3.6Mg Implant, Goserelin acetate 3.6 mg, Zoladex LA, Goserelin acetate 10.8 mg, Decapeptyl sustained release 22.5 mg, Triptorelin 11.25 mg, Decapeptyl sustained release 11.25 mg, Depo-Eligard 45 mg, Leuprorelin acetate 45 mg, Depo-Eligard 22.5 mg, Leuprorelin acetate 22.5 mg, Depo-Eligard 7.5 mg, Leuprorelin acetate 7.5 mg, Firmagon 120 MG Injection, Degarelix 40 mg, Firmagon 80 MG Injection, Degarelix 20 mg, Docetaxel, Taxotere | Cancer Research Antwerp, Bayer, Veracyte, Inc. | Prostate Cancer | 07/30 | 12/30 | | |
